Clinical Trial Update: Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating epirubicin in combination with celecoxib for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CELEBREX (Celecoxib)
• ELLENCE (Epirubicin hydrochloride)

Snippet

Sponsor: Northwestern University | Conditions: Liver Cancer | Phase 1, Phase 2 | Status: COMPLETED